Topics

Golden Leaf Holdings Ltd. Announces New Interim CFO

20:00 EDT 12 Sep 2019 | Globe Newswire

TORONTO, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) (“Golden Leaf” of the “Company”), a cannabis company with cultivation, production and retail operations built around recognized brands, announced today that the Company’s Board of Directors has appointed Ekaterina (“Kate”) Koustareva as Interim CFO, while the Company continues its search for a permanent CFO. Ms. Koustareva will begin her duties effective immediately.

Jeff Yapp, CEO stated, “The Company appreciates Kate for stepping up to take this interim role.  Kate has demonstrated a strong work ethic, attention to detail and a commitment to the Company.  Her experience and guidance will be a great assets during this growth and transition period.”  

To be added to the distribution list, please email GLH@kcsa.com with “GLH” in the subject line. 

About Golden Leaf Holdings

Golden Leaf Holdings Ltd. is a Canadian company with operations in multiple jurisdictions including Oregon, Nevada, and Canada, with cultivation, production and retail operations built around recognized brands. Golden Leaf distributes its products through its branded Chalice Farms retail dispensaries, as well as through third-party dispensaries. Golden Leaf’s cannabis retail operations and products are designed with the customer in mind, focused on superlative in-store experience and quality products. Visit www.goldenleafholdings.com to learn more.

Investor Relations:
Steve Hosein
Renmark Financial Communications
416-644-2020
shosein@renmarkfinancial.com

John Varghese
Executive Chairman
Golden Leaf Holdings Ltd.
971-371-2685
ir@goldenxtrx.com

Media Relations:
Anne Donohoe / Nick Opich
KCSA Strategic Communications
adonohoe@kcsa.com/ nopich@kcsa.com
212-896-1265 / 212-896-1206

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Golden Leaf Holdings Ltd. Announces New Interim CFO"

Quick Search

Relevant Topic

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...